{"id":178254,"date":"2026-01-28T15:10:35","date_gmt":"2026-01-28T20:10:35","guid":{"rendered":"https:\/\/alphastreet.com\/india\/?p=178254"},"modified":"2026-01-28T15:10:35","modified_gmt":"2026-01-28T20:10:35","slug":"vimta-labs-q3-revenue-rises-10-profit-flat-amid-margin-pressure","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/vimta-labs-q3-revenue-rises-10-profit-flat-amid-margin-pressure\/","title":{"rendered":"Vimta Labs Q3 Revenue Rises 10%, Profit Flat Amid Margin Pressure"},"content":{"rendered":"\n

Vimta Labs Ltd.<\/strong> (NSE: VIMTALABS) on Wednesday reported a modest rise in quarterly revenue for the three months ended Dec. 31, 2025, while net profit was largely flat year-on-year and margins showed signs of pressure compared with the prior quarter.<\/p>\n\n\n\n

For the third quarter of fiscal 2026 (Q3 FY26), the contract research and testing services provider posted total income of \u20b91,005 million<\/strong>, up 10.2% from \u20b9911 million<\/strong> in the year-ago quarter. On a sequential basis, revenue declined 3.9% from \u20b91,045 million<\/strong> in Q2 FY26.<\/p>\n\n\n\n

Net profit after tax (PAT) from continuing operations was \u20b9176 million<\/strong>, essentially flat year-on-year (\u20b9175 million)<\/strong> but down 11.7%<\/strong> on a quarter-on-quarter basis (\u20b9199 million). Basic earnings per share were \u20b94.0<\/strong>, compared with \u20b93.9 a year ago<\/strong> and \u20b94.5 in Q2 FY26<\/strong>.<\/p>\n\n\n\n

EBITDA was \u20b9344 million<\/strong>, up 0.4% from \u20b9343 million<\/strong> in Q3 FY25 but down 6.6% from \u20b9369 million<\/strong> in the previous quarter. The EBITDA margin narrowed to 34.3% from 35.3% in Q2 FY26 and 37.6% in Q3 FY25<\/strong>. PAT margin also edged lower to 17.5%<\/strong> from 19.1%<\/strong> sequentially and 19.2%<\/strong> a year earlier.<\/p>\n\n\n\n

In the nine months ended Dec. 31, 2025, total income rose 20.7% to \u20b93,043 million<\/strong> from \u20b92,521 million in the same period last year. EBITDA for the nine-month period was \u20b91,068 million<\/strong>, up 16.7%<\/strong> with a margin of 35.1%<\/strong>, while PAT grew 16.4% to \u20b9564 million<\/strong>. Basic EPS for 9M FY26 was \u20b912.7<\/strong> versus \u20b910.9<\/strong> in the prior year.<\/p>\n\n\n\n

The company\u2019s profit before tax (PBT) for the quarter was \u20b9234 million<\/strong>, down from \u20b9263 million in the prior quarter, and \u20b9749 million for the nine-month period<\/strong> versus \u20b9640 million a year earlier.<\/p>\n\n\n\n

Operational and Segment Highlights<\/strong><\/h2>\n\n\n\n

Vimta Labs\u2019 board noted it has only one reportable segment \u2014 contract research and testing services<\/strong>, which encompasses clinical research, bioanalytical, and other testing services. There were no separate financial disclosures provided for sub-segments in the regulatory filings.<\/p>\n\n\n\n

The company said it completed the sale of its diagnostics and pathological services business in October 2024<\/strong>, and prior period figures for profit and loss have been regrouped to ensure comparability with the current period.<\/p>\n\n\n\n

Management commentary emphasized demand across service offerings and improved operational efficiencies while acknowledging the impact of new labor codes, which was reflected as an exceptional item<\/strong> in the quarter.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Costs and Margins<\/strong><\/h2>\n\n\n\n

Total expenses in Q3 FY26 were \u20b9644 million, slightly lower than \u20b9676 million in Q2 but higher than \u20b9568 million a year ago, driven by employee benefits and other operational costs. Material and testing costs remained broadly stable.<\/p>\n\n\n\n

Industry Context<\/strong><\/h2>\n\n\n\n

India\u2019s contract research and testing sector has been expanding amid growing pharmaceutical development activity and regulatory scrutiny across food, environmental, and healthcare testing. However, macroeconomic pressures and regulatory changes such as updated labor laws have posed cost challenges for laboratories nationwide.<\/p>\n\n\n\n

Company Description<\/strong><\/h2>\n\n\n\n

Vimta Labs Ltd, headquartered in Hyderabad, India, is a contract research and testing organization offering a range of scientific and regulatory services spanning drug discovery and development, bioanalytical testing, clinical research, food and environmental testing, and related services. It divested its diagnostics and pathological services business in late 2024.<\/p>\n","protected":false},"excerpt":{"rendered":"

Vimta Labs Ltd. (NSE: VIMTALABS) on Wednesday reported a modest rise in quarterly revenue for the three months ended Dec. 31, 2025, while net profit was largely flat year-on-year and margins showed signs of pressure compared with the prior quarter. For the third quarter of fiscal 2026 (Q3 FY26), the contract research and testing services […]<\/p>\n","protected":false},"author":2399,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1941,392,5747],"tags":[12441,14980,8157,12200,14978,14979],"class_list":["post-178254","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-stock-analysis","category-earnings","category-healthcare-stocks","tag-contract-research","tag-crto","tag-healthcare","tag-quality-testing","tag-vimta-labs","tag-vimtalabs"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":150346,"url":"https:\/\/alphastreet.com\/india\/vimta-labs-ltd-q1fy24-4-rise-in-revenue\/","url_meta":{"origin":178254,"position":0},"title":"Vimta Labs Ltd Q1FY24; 4% rise in Revenue","author":"Chirag Gupta","date":"July 28, 2023","format":false,"excerpt":"Vimta Labs Limited is testing food and drugs. It also does contract research for clinical research and pre-clinical studies provider in India. It provides analytical, clinical and preclinical services to life sciences industries; quality and safety testing for food and beverage industries; and environment services to a wide spectrum of\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/07\/image-354.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/07\/image-354.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/07\/image-354.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/07\/image-354.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/07\/image-354.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/07\/image-354.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":178666,"url":"https:\/\/alphastreet.com\/india\/vimta-labs-ltd-vimtalabs-q3-2026-earnings-call-transcript\/","url_meta":{"origin":178254,"position":1},"title":"VIMTA LABS LTD (VIMTALABS) Q3 2026 Earnings Call Transcript","author":"News desk","date":"January 30, 2026","format":false,"excerpt":"VIMTA LABS LTD (NSE: VIMTALABS) Q3 2026 Earnings Call dated Jan. 28, 2026 Corporate Participants: Siva Rama Kambhampati \u2014 Chief Financial Officer Harita Vasireddi \u2014 Managing Director and Whole Time Director Satya Neerukonda \u2014 Executive Director Analysts: Vishal Manchanda \u2014 Analyst Preet Jain \u2014 Analyst Disha \u2014 Analyst Santosh Keshari\u2026","rel":"","context":"In "Earnings Call Transcripts"","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":145200,"url":"https:\/\/alphastreet.com\/india\/vimta-labs-ltd-vimtalabs-q4-fy23-earnings-concall-transcript\/","url_meta":{"origin":178254,"position":2},"title":"VIMTA LABS LTD (VIMTALABS) Q4 FY23 Earnings Concall Transcript","author":"IRS_INDIA","date":"May 7, 2023","format":false,"excerpt":"VIMTA LABS LTD (NSE:VIMTALABS) Q4 FY23 Earnings Concall dated May. 05, 2023. Corporate Participants: Vishal Manchanda\u00a0--\u00a0Vice President, Institutional Research Narahari Naidu\u00a0--\u00a0Chief Financial Officer Harita Vasireddi\u00a0--\u00a0Managing Director Analysts: Sunil Kothari\u00a0--\u00a0Unique PMS -- Analyst Dhwanil Desai\u00a0--\u00a0Turtle Capital -- Analyst Ankit Gupta\u00a0--\u00a0Bamboo Capital -- Analyst Jigar Shroff\u00a0--\u00a0Financial Research Technologies -- Analyst Aman Vij\u00a0--\u00a0Astute\u2026","rel":"","context":"In "Earnings Call Transcripts"","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"Earnings Conference Call Transcript","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":174015,"url":"https:\/\/alphastreet.com\/india\/vimta-labs-ltd-vimtalabs-q2-2025-earnings-call-transcript\/","url_meta":{"origin":178254,"position":3},"title":"VIMTA LABS LTD (VIMTALABS) Q2 2025 Earnings Call Transcript","author":"News desk","date":"January 22, 2026","format":false,"excerpt":"VIMTA LABS LTD (NSE: VIMTALABS) Q2 2025 Earnings Call dated Nov. 08, 2024 Corporate Participants: Narahari Naidu \u2014 Chief Financial Officer Harita Vasireddi \u2014 Managing Director Analysts: Vishal Manchanda \u2014 Analyst Viraj Mehta \u2014 Analyst Ankit Gupta \u2014 Analyst Ankeet Pandya \u2014 Analyst Milan Shah \u2014 Analyst Vignesh Iyer \u2014\u2026","rel":"","context":"In "Earnings Call Transcripts"","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":180635,"url":"https:\/\/alphastreet.com\/india\/vedant-fashions-ltd-stock-slips-as-q3-fy26-revenue-profit-contract\/","url_meta":{"origin":178254,"position":4},"title":"Vedant Fashions Ltd stock slips as Q3 FY26 revenue, profit contract","author":"Staff Correspondent","date":"February 13, 2026","format":false,"excerpt":"Vedant Fashions Ltd (NSE: MANYAVAR, BSE: 543463) shares closed at about \u20b9460.55 on the NSE on February 13, 2026, trading lower by approximately 1.1% during the session, reflecting market reaction to latest financial disclosures. Market Capitalization The company\u2019s market capitalization stood near \u20b911,400 crore at the latest close. Latest Quarterly\u2026","rel":"","context":"In "LATEST"","block_context":{"text":"LATEST","link":"https:\/\/alphastreet.com\/india\/category\/latest\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":174014,"url":"https:\/\/alphastreet.com\/india\/vimta-labs-ltd-vimtalabs-q4-2025-earnings-call-transcript\/","url_meta":{"origin":178254,"position":5},"title":"VIMTA LABS LTD (VIMTALABS) Q4 2025 Earnings Call Transcript","author":"News desk","date":"January 22, 2026","format":false,"excerpt":"VIMTA LABS LTD (NSE: VIMTALABS) Q4 2025 Earnings Call dated Apr. 28, 2025 Corporate Participants: Unidentified Speaker Vishal Manchanda \u2014 Investor Relations Harita Vasireddi \u2014 Managing Director Analysts: Raheel Shah \u2014 Analyst Ajay Surya \u2014 Analyst Vignesh Iyer \u2014 Analyst Ankit Gupta \u2014 Analyst Kiran \u2014 Analyst Kaushal Sharma \u2014\u2026","rel":"","context":"In "Earnings Call Transcripts"","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/178254","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/2399"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=178254"}],"version-history":[{"count":1,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/178254\/revisions"}],"predecessor-version":[{"id":178258,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/178254\/revisions\/178258"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=178254"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=178254"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=178254"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}